Start here if you're new
what it is
It makes safety syringes and related needle products for hospitals and clinics.
how it gets paid
Last year Rvp made $33M in revenue. VanishPoint syringes was the main engine at $12M, or 36% of sales.
what just happened
$29M in quarterly revenue looks strong until you see a 5.5% gross margin.
At a glance
C++ balance sheet — some cracks in the foundation
25/100 earnings predictability — expect surprises
4.8% return on capital — nothing to write home about
-$0.40 fy2024 eps est
$2B fy2026 rev est
xvary composite: 41/100 — below average
What they do
It makes safety syringes and related needle products for hospitals and clinics.
A company with 221 employees sold $33M of needle-avoidance gear. You are not buying a brand people brag about. You are buying a device that retracts the needle after use, because the alternative is a stick and a report.
How they make money
$33M
annual revenue
VanishPoint syringes
$12M
VanishPoint blood collection
$5M
VanishPoint IV catheters
$4M
Patient Safe syringes
$7M
EasyPoint needles
$5M
The products that matter
retractable safety syringes
VanishPoint®
brand-level sales not disclosed
it sits inside the same $33M annual revenue base, which means even the flagship product is not being broken out as a separate growth engine in this snapshot.
core brand
patient safety syringes
Patient Safe®
brand-level sales not disclosed
this brand matters because the company needs every product line pulling its weight, and right now the combined business still posted a -2.42% gross margin.
same margin problem
blood collection needles
EasyPoint®
brand-level sales not disclosed
it broadens the catalog, but the only number you can actually anchor to here is $33M of total revenue for the whole company. That is thin disclosure, and you should treat it that way.
no segment breakout
Key numbers
$33M
annual revenue
Revenue → money in the door → the whole business is small, so one weak quarter matters more than it should.
63.9%
operating margin
Operating margin → profit after running the business → for every $1 sold, 64 cents disappear before interest and taxes.
5.5%
gross margin
Gross margin → sales left after direct costs → only 5.5 cents of each dollar survive the factory floor.
$1M
long-term debt
Debt → borrowed money → the balance sheet is light, but the earnings math is still ugly.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 3 — safer than 50% of stocks
- price stability 15 / 100
- long-term debt $1M (3% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for RVP right now.
source: institutional data · return history unavailable
What just happened
missed estimates
$29M in quarterly revenue looks strong until you see a 5.5% gross margin.
Revenue was $29M, up 186% vs. prior year, but EPS was -$0.35 and gross margin was only 5.5%. The top line moved fast. The profit line did not.
$29M
revenue
-$0.35
eps
5.5%
gross margin
the number that mattered
5.5% gross margin matters most because it shows how little of each sale survives after direct costs.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk here is negative gross margin on safety syringe sales. For Retractable Technologies, that means the core product set is not covering its own production cost.
med
Negative gross margin
Gross margin is -2.42%. In plain English: every additional sale currently adds revenue but does not add economic relief.
If that stays negative, scaling the business just scales the problem.
med
Operating losses are still severe
Operating margin sits at -49.1%. That means nearly half of revenue is being lost after operating expenses are counted.
Even a modest revenue rebound would not fix this without major cost improvement.
med
Sales are moving the wrong way
Annual revenue fell 24.1% to $33M. Turnarounds get harder when the top line is shrinking while margins are already negative.
Less revenue leaves less room to absorb fixed costs and makes the margin repair job steeper.
A -2.42% gross margin, -49.1% operating margin, and 24.1% revenue decline tell you this is not one bad quarter. It is a business model repair job.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
March 26, 2026 report
This is the next hard checkpoint. If gross margin is still below zero, the turnaround case stays theoretical.
metric
gross margin first
Watch the -2.42% gross margin before anything else. Positive gross margin is the minimum entry ticket to a real recovery story.
risk
cash burn vs. balance sheet
Long-term debt is only $1M, which helps, but losses still matter. If operations stay this weak, low debt does not save the equity on its own.
trend
revenue stabilization
A 24.1% sales drop is too large to ignore. You want to see the top line stop shrinking before you start talking about durable upside.
Analyst rankings
earnings predictability
25 / 100
A 25/100 predictability score means the earnings path is shaky. In human-speak, you should expect messy quarters and limited visibility.
risk rank
3
Risk rank 3 says the stock is not uniquely radioactive on broad screens, but the business quality is weaker than the rank alone suggests.
price stability
15 / 100
A 15/100 stability score means the stock does not trade like a safe parking place. You should expect sharp moves.
source: institutional data
Institutional activity
institutional ownership data for RVP is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive